High concentration medicant solutions for treating neurological disorders
AssigneesCerebral Therapeutics, Inc., The Regents of the University of Colorado
InventorsDaniel J. Abrams, Thomas Joseph Anchordoquy
Life of this patent
Estimating the term…
Abstract
Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.
Claims16
A method of ameliorating a symptom of epilepsy in a subject, comprising:
- administering directly to the brain of a subject a medicament for ameliorating the symptom of epilepsy over a time period of at least two days, wherein the medicament exhibits a half-life of less than 2 hours in cerebrospinal fluid and wherein the administered medicament has a concentration from 100 mg/mL to 500 mg/mL;
- determining medicament concentration by sampling blood serum and performing a test of medicament concentration in the sampled blood serum;
- and
- changing daily flow rate and/or concentration of the administered medicament based on the medicament concentration in the sampled blood serum to achieve a concentration in the blood serum of between about 1 microgram/mL to 500 microgram/mL,
- wherein the medicament comprises valproic acid or a pharmaceutically active derivative thereof.
A method of ameliorating a symptom of epilepsy, comprising:
- administering a medicament with a catheter directly to the brain of a subject, wherein the medicament comprises a half-life of less than 2 hours in cerebrospinal fluid and wherein the administered medicament has a concentration from 100 mg/mL to 500 mg/mL;
- determining medicament concentration by sampling blood serum and performing a test of the concentration of medicament in the sampled blood serum;
- and
- changing daily flow rate and/or concentration of the administered medicament based on the concentration of the medicament in the sampled blood serum to achieve a concentration in the blood serum of between about 1 microgram/mL to 500 microgram/mL,
- wherein the medicament ameliorates and/or modifies the epilepsy,
- wherein the medicament comprises valproic acid or a pharmaceutically active derivative thereof.
A method of ameliorating seizures of a patient diagnosed with epilepsy, comprising:
- administering directly to cerebrospinal fluid of a patient's brain a formulation comprised of valproic acid or a pharmaceutically acceptable salt thereof, wherein the valproic acid of the pharmaceutically acceptable salt thereof has a half-life of less than 2 hours in cerebrospinal fluid and has a concentration in the formulation from 100 mg/mL to 500 mg/mL;
- continuing the administration directly to cerebrospinal fluid of the patient's brain over a period of days;
- determining a concentration of the valproic acid or the pharmaceutically acceptable salt thereof by sampling blood serum and performing a test of the concentration of the valproic acid or the pharmaceutically acceptable salt thereof in the sampled blood serum;
- and
- changing daily flow rate and/or concentration of the administered formulation based on the concentration of the valproic acid or the pharmaceutically acceptable salt thereof in the sampled blood serum to achieve a concentration in the blood serum of between about 1 microgram/mL to 500 microgram/mL.
Dependencies are inferred from the claim text.